Tekla Begin Period Cash Flow from 2010 to 2025

HQH Stock  USD 16.49  0.09  0.54%   
Tekla Healthcare's Begin Period Cash Flow is increasing with very volatile movements from year to year. Begin Period Cash Flow is predicted to flatten to 233.80. Begin Period Cash Flow is the amount of cash Tekla Healthcare Investors has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
1996-03-31
Previous Quarter
792
Current Value
214
Quarterly Volatility
15.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 188.3 K, Interest Expense of 0.0 or Selling General Administrative of 13.2 M, as well as many indicators such as Price To Sales Ratio of 73.81, Dividend Yield of 0.0222 or PTB Ratio of 1.0. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
  
Check out the analysis of Tekla Healthcare Correlation against competitors.

Latest Tekla Healthcare's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Tekla Healthcare Investors over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Tekla Healthcare's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Very volatile
   Begin Period Cash Flow   
       Timeline  

Tekla Begin Period Cash Flow Regression Statistics

Arithmetic Mean232,247
Geometric Mean2,305
Coefficient Of Variation242.69
Mean Deviation376,289
Median927.00
Standard Deviation563,636
Sample Variance317.7B
Range1.7M
R-Value0.09
Mean Square Error337.6B
R-Squared0.01
Significance0.74
Slope10,618
Total Sum of Squares4.8T

Tekla Begin Period Cash Flow History

2025 233.8
2024 246.1
2023 214.0
2022 792.0
2021 935.0
20191.7 M

About Tekla Healthcare Financial Statements

Investors use fundamental indicators, such as Tekla Healthcare's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Begin Period Cash Flow 246.10  233.80 

Currently Active Assets on Macroaxis

When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:
Check out the analysis of Tekla Healthcare Correlation against competitors.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.145
Dividend Share
2.04
Earnings Share
3.53
Revenue Per Share
0.207
Quarterly Revenue Growth
0.172
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.